The researchers believe, however, that despite these promising findings, the limitations in the study prevent the formation of solid conclusions on the smoking cessation effects of semaglutide
FDA conducted a meta-analysis of 91 placebo-controlled GLP-1 RA trials (107,910 patients: 60,338 on GLP-1 RA, 47,572 on placebo), finding no increased SI/B risk or related psychiatric events like anxiety, depression, irritability, or psychosis
It just removes the safeguard
This medication, which contains semaglutide, functions by mimicking the GLP-1 hormone to control blood sugar levels
Its main active compounds, oleuropein and hydroxytyrosol, disrupt fungal membranes, inhibit biofilm formation, and enhance immune defenses